Patents by Inventor Kelly L. Smith
Kelly L. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9028870Abstract: A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.Type: GrantFiled: December 27, 2010Date of Patent: May 12, 2015Assignee: Bend Research, Inc.Inventors: Leah E. Appel, Ronald A. Beyerinck, Mark B. Chidlaw, William J. Curatolo, Dwayne T. Friesen, Kelly L. Smith, Avinash G. Thombre
-
Publication number: 20110182947Abstract: A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.Type: ApplicationFiled: December 27, 2010Publication date: July 28, 2011Inventors: Leah E. Appel, Ronald A. Beyerinck, Mark B. Chidlaw, William J. Curatolo, Dwayne T. Friesen, Kelly L. Smith, Avinash G. Thombre
-
Patent number: 7446860Abstract: A method and system for determining range to a target are provided. A beam of electromagnetic energy is transmitted through an aperture in an opaque screen such that a portion of the beam passes through the aperture to generate a region of diffraction that varies as a function of distance from the aperture. An imaging system is focused on a target plane in the region of diffraction with the generated image being compared to known diffraction patterns. Each known diffraction pattern has a unique value associated therewith that is indicative of a distance from the aperture. A match between the generated image and at least one of the known diffraction patterns is indicative of a distance between the aperture and target plane.Type: GrantFiled: September 18, 2006Date of Patent: November 4, 2008Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space AdministrationInventors: Jonathan W. Campbell, David L. Lehner, Larry L. Smalley, Molly C. Smith, legal representative, Alvin J. Sanders, Dennis Duncan Earl, Stephen W. Allison, Kelly L. Smith
-
Publication number: 20020015731Abstract: A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.Type: ApplicationFiled: December 20, 2000Publication date: February 7, 2002Inventors: Leah E. Appel, Ronald A. Beyerinck, Mark B. Chidlaw, William J. Curatolo, Dwayne T. Friesen, Kelly L. Smith, Avinash G. Thombre
-
Patent number: 5888930Abstract: A durable and sprayable controlled release bead of active ingredient in the pores of a polymeric micro-porous bead having an anisotropic pore structure of large pores in the interior and small pores at the surface, the gradation of pore sizes between the interior and the surface being continuous.Type: GrantFiled: March 13, 1997Date of Patent: March 30, 1999Assignee: Bend Research, Inc.Inventors: Kelly L. Smith, Matthew F. Holmes, James W. Brooke
-
Patent number: 5827538Abstract: An osmotic device that, following the imbibement of water vapor, provides for the controlled release of a beneficial agent to an aqueous environment. The device comprises a hydrophilic formulation including a beneficial agent, and if needed, an osmagent, surrounded by a wall. The wall is formed at least in part of a semipermeable hydrophobic membrane having an average pore size between about 0.1 .mu.m and 30 .mu.m. The pores are substantially filled with a gas phase. The hydrophobic membrane is permeable to water in the vapor phase and the hydrophobic membrane is impermeable to an aqueous medium at a pressure less than about 100 Pa. The beneficial agent is released, for example, by osmotic pumping or osmotic bursting upon imbibement of sufficient water vapor into the device core.Type: GrantFiled: January 17, 1996Date of Patent: October 27, 1998Assignee: Pfizer Inc.Inventors: Edward L. Cussler, Scott M. Herbig, Kelly L. Smith, Paul van Eikeren
-
Patent number: 5750126Abstract: There is disclosed a pesticidal composition comprising a pH-sensitive non-lignin-based polymer encapsulating both the active agent and a lignin-based UV screening agent.Type: GrantFiled: January 11, 1996Date of Patent: May 12, 1998Assignee: Bend Research, Inc.Inventors: Kelly L. Smith, Scott H. Herbig
-
Patent number: 5698220Abstract: A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.Type: GrantFiled: June 5, 1995Date of Patent: December 16, 1997Assignee: Pfizer Inc.Inventors: John R. Cardinal, Scott M. Herbig, Richard W. Korsmeyer, Jeelin Lo, Kelly L. Smith, Avinash G. Thombre
-
Patent number: 5612059Abstract: A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.Type: GrantFiled: September 25, 1992Date of Patent: March 18, 1997Assignee: Pfizer Inc.Inventors: John R. Cardinal, Scott M. Herbig, Richard W. Korsmeyer, Jeelin Lo, Kelly L. Smith, Avinash G. Thombre
-
Patent number: 5609590Abstract: An osmotic bursting device for dispensing a beneficial agent to an aqueous environment. The device comprises a beneficial agent and osmagent surrounded at least in part by a semipermeable membrane. Alternatively the beneficial agent may also function as the osmagent. The semipermeable membrane is permeable to water and substantially impermeable to the beneficial agent and osmagent. A trigger means is attached to the semipermeable membrane (e.g., joins two capsule halves). The trigger means is activated by a pH of from 3 to 9 and triggers the eventual, but sudden, delivery of the beneficial agent. These devices enable the pH-triggered release of the beneficial agent core as a bolus by osmotic bursting.Type: GrantFiled: October 19, 1994Date of Patent: March 11, 1997Assignee: Pfizer Inc.Inventors: Scott M. Herbig, Kelly L. Smith
-
Patent number: 5603953Abstract: Supported liquid membrane delivery devices that release a beneficial agent to an aqueous environment following exposure to an environmental trigger. A microporous hydrophobic support membrane at least partially surrounds a beneficial agent- containing hydrophilic formulation. A hydrophobic liquid is held within the microporous support membrane by capillarity and the hydrophobic liquid is substantially permeable to the aqueous environment and the beneficial agent-containing hydrophilic formulation. The entrained hydrophobic liquid becomes substantially permeable to the aqueous environment upon exposure to an environmental trigger such as an enzyme, and the beneficial agent is subsequently released.Type: GrantFiled: May 23, 1995Date of Patent: February 18, 1997Assignee: Pfizer Inc.Inventors: Scott M. Herbig, Kelly L. Smith, Paul Van Eikeren, James B. West
-
Patent number: 5358502Abstract: An osmotic bursting device for dispensing a beneficial agent to an aqueous environment. The device comprises a beneficial agent and osmagent surrounded at least in part by a semipermeable membrane. Alternatively the beneficial agent may also function as the osmagent. The semipermeable membrane is permeable to water and substantially impermeable to the beneficial agent and osmagent. A trigger means is attached to the semipermeable membrane (e.g., joins two capsule halves). The trigger means is activated by a pH of from 3 to 9 and triggers the eventual, but sudden, delivery of the beneficial agent. These devices enable the pH-triggered release of the beneficial agent core as a bolus by osmotic bursting.Type: GrantFiled: February 25, 1993Date of Patent: October 25, 1994Assignee: Pfizer IncInventors: Scott M. Herbig, Kelly L. Smith
-
Patent number: 4948506Abstract: Interfacially-polymerized ultrathin films containing physicochemically functional groups are disclosed, both with and without supports. Various applications are disclsoed, including membrane electrodes, selective membranes and sorbents, biocompatible materials, targeted drug delivery, and narrow band optical absorbers.Type: GrantFiled: November 14, 1988Date of Patent: August 14, 1990Assignee: Bend Research, Inc.Inventors: Harold K. Lonsdale, Walter C. Babcock, Dwayne T. Friensen, Kelly L. Smith, Bruce M. Johnson, Carl C. Wamser
-
Patent number: 4769027Abstract: Prills of pharmaceutically acceptable material are coated first with a water-permeable polymeric matrix containing a water-soluble pharmaceutically beneficial agent and then overcoated with a water-permeable film containing dispersed therein a water-soluble, particulate pore-forming material.Type: GrantFiled: February 24, 1987Date of Patent: September 6, 1988Assignee: Burroughs Wellcome Co.Inventors: Richard W. Baker, Kelly L. Smith, James W. Brooke
-
Patent number: 4127127Abstract: Therapeutic systems in the form of drug-containing bags or packets made from films of segmented copolyesters of butylene terephthalate and polyalkylene ether terephthalate are disclosed.Type: GrantFiled: May 23, 1977Date of Patent: November 28, 1978Assignee: Alza CorporationInventors: Patrick S. L. Wong, Kelly L. Smith, Alan S. Michaels